EFTA00550654.pdf

From: J <[email protected]> To: ICatyna Shuliak Subject: Re: Accutane Date: Wed, 02 Jan 2019 13:54:08 +0000 Yes , I have read and re-read In addition on the prescribing information it states that if lipids after the first month have not dramatically increased , no further test should be required. . As my lipid levels have not changed from before and after , what would you need , for this months prescription? On Wed, Jan 2, 2019 at 8:47 AM > wrote: Begin forwarded message: From: Ellen Marmur Date: January 2 2019 at 8:31:53 AM EST To: , Lena Ladenheim , Renee O'Brien Subject: Re: Accutane Dear Happy New Year. Please see this https://www.ncbi.nlm.nih.gov/pubmed/16971314 from the government website. Do you have your copy of the ipledge agreement you signed? Dr. Marmur On Fri, Dec 28, 2018 at 12:22 PM 'Ma wrote: Dear Dr Marmur, Hope you are enjoying your holidays. I would like to make sure I understand my obligations re future blood tests in order that I continue on the Accutane. I understand now that the only test I must take for you is the pregnancy test. If this is not the case please let me know as soon as possible and I would appreciate being pointed to the reference that you believe requires it. Thank you. Dr. Ellen Marmur President/Founder, Marmur Medical 12 East 87th Street, Suite IA NY, NY 10128 Associate Clinical Professor, The Department of Dermatology EFTA00550654  Associate Clinical Professor, The Department of Genomics & Genetic Science The Mount Sinai Medical Center New York, New York 10029 •SECURITY/CONFIDENTIALITY WARNING: This message and any attachments are intended solely for the individual or entity to which they are addressed. This communication may contain information that is privileged, confidential, or exempt from disclosure under applicable law (e.g., personal health information, research data, financial information). Because this e-mail has been sent without encryption, individuals other than the intended recipient may be able to view the information, forward it to others or tamper with the information without the knowledge or consent of the sender. If you are not the intended recipient, any dissemination, distribution or copying of the communication is strictly prohibited. If you received the communication in error, please notify the sender immediately by replying to this message and deleting the message and any accompanying files from your system. If, due to the security risks, you do not wish to receive further communications via e-mail, please reply to this message and inform the sender that you do not wish to receive further e-mail from the sender. please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to , and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00550655